Healthy Clinical Trial
— PANFLUVACOfficial title:
Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults
Verified date | November 2019 |
Source | University of Bergen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or
without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated
locally and systemically and by using haematological, biochemical and immunological screening
tests. The immunogenicity of the H5N1 vaccine will be assessed through the induction of local
and systemic antibody and cellular immune responses. In a pandemic situation, an important
aspect is the rapidity of the immune response to the H5N1 vaccine so the detailed kinetics of
the immune response will be investigated. The capacity of the vaccine to elicit long lasting
immunity and cross reactive immunity to H5 viruses will also be evaluated. Furthermore, the
quality of the immune response induced by the vaccine will be studied. The vaccine will be
administered as twice the normal human dose (30μg HA) with and without adjuvant, and in a
dose sparing manor of half (7.5μg HA) and one tenth (1.5μg HA) of the normal human dose with
adjuvant. Sixty subjects will receive two doses of virosomal H5N1 influenza vaccine
(separated by 21 ± 4 days) by intramuscular injection into the deltoid muscle. Escalating
doses will be separated by a period of one week. Four groups each containing 15 subjects will
receive two doses of the pandemic virosomal A/H5N1 influenza vaccine containing:
Group 1 30µg HA IM, Group 2 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 3
7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 4 30µg HA adjuvanted with 50µg
3rd generation ISCOM™ IM.
Status | Completed |
Enrollment | 60 |
Est. completion date | November 2013 |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old - Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine - Signed informed consent - Subjects able to understand and comply with the study protocol and complete the Adverse Event Form - Subjects able to attend the scheduled visits - Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator Exclusion Criteria: - Persons with a history of anaphylaxis or serious reactions to any vaccine - Persons with known hypersensitivity to any of the vaccine components - Persons who have had a temperature >38oC during the previous 72 hours - Persons who have had an acute respiratory infection during the last 7 days - Women who are pregnant or breast-feeding - Persons with chronic illness at any stage that could interfere with trial conduct or compliance - Persons who have received blood products or immunoglobulins parenterally during the previous 3 months - Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination - Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs - Persons taking immunostimulant therapy - Persons involved in another clinical trial during the last month. - Suspected non-compliance |
Country | Name | City | State |
---|---|---|---|
Norway | Haukeland Univeristy Hospital | Bergen |
Lead Sponsor | Collaborator |
---|---|
Rebecca Cox | European Commission, Haukeland University Hospital |
Norway,
Cox RJ, Major D, Pedersen G, Pathirana RD, Hoschler K, Guilfoyle K, Roseby S, Bredholt G, Assmus J, Breakwell L, Campitelli L, Sjursen H. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Pro — View Citation
Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nøstbakken JK, Weverling GJ, Klap J, McCullough KC, Zambon M, Kompier R, Sjursen H. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ a — View Citation
Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep — View Citation
Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccinat — View Citation
Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis. 2012 Jul 15;206(2):158-66. doi: 10.1093/infdis/jis330. Epub 2012 May 2. — View Citation
Pedersen GK, Sjursen H, Nøstbakken JK, Jul-Larsen Å, Hoschler K, Cox RJ. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. Hum Vaccin Immunother. 2014;10(8):2408-16. doi: 10.4161/hv.29583. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Solicted Adverse Events | The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant. | three months | |
Primary | Adverse Events | 42 days | ||
Secondary | Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | Number of participants with haemagglutination inhibition tigers >= 32 at the long term time point (1 year post vaccination). | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |